Pre-made Cantuzumab Mertansine benchmark antibody (Whole mAb ADC, anti-MUC1 therapeutic antibody, Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Cantuzumab Mertansine benchmark antibody (Whole mAb ADC, anti-MUC1 therapeutic antibody, Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cantuzumab mertansine (SB-4875; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer.[1] It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1).[2] It was developed by ImmunoGen.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-769-1mg	1mg	Inquiry
GMP-Bios-INN-769-10mg	10mg	Inquiry
GMP-Bios-INN-769-100mg	100mg	Inquiry
GMP-Bios-INN-769-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Cantuzumab Mertansine Biosimilar, Whole Mab Adc, Anti-Muc1 Antibody: Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM therapeutic antibody Drug Conjugate
INN Name	Cantuzumab Mertansine
Target	MUC1
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	GlaxoSmithKline (Brentford UK) / ImmunoGen Inc. (Cambridge MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0